meropenem/vaborbactam (Vabomere)
Jump to navigation
Jump to search
Indications
- complicated urinary tract infection in adults including pyelonephritis, caused by designated susceptible Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae (FDA-approved 8/2017)[1]
- ventilator-associated pneumonia (FDA-approved)[3]
* superior to piperacillin tazobactam; 98% symptom-free & culture negative vs 94%[1][2]
* noninferior to piperacillin tazobactam[2]
Dosage
- 4 g (meropenem 2 g, vaborbactam 2 g) IV infusion over 3-hours every 8 hours (GFR > 50 mL/min per 1.73 m2)
- up to 14 days of treatment
Adverse effects
- most common:
- serious:
More general terms
Components
References
- ↑ 1.0 1.1 1.2 Brooks M FDA OKs Vabomere, New Antibacterial for Complicated UTI Medscape - Aug 30, 2017. http://www.medscape.com/viewarticle/885026
FDA News Release. Aug 29, 2017 FDA approves new antibacterial drug. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ 2.0 2.1 2.2 Kaye KS, Bhowmick T, Metallidis S et al Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract InfectionThe TANGO I Randomized Clinical Trial. JAMA. 2018;319(8):788-799. February 27, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29486041 https://jamanetwork.com/journals/jama/fullarticle/2673552
- ↑ 3.0 3.1 Rapid Review Quiz: Hospital-Acquired Pneumonia Medscape. Sept 15, 2022 https://reference.medscape.com/viewarticle/980567
- ↑ VABOMERE Prescribing information http://www.vabomere.com/media/pdf/vabomere-us-prescribing-information.pdf